Association between high dose catecholamine support and liver dysfunction following cardiac surgery

J Card Surg. 2020 Jun;35(6):1228-1236. doi: 10.1111/jocs.14555. Epub 2020 Apr 25.

Abstract

Background: Cardiac surgery using cardiopulmonary bypass is a well-established procedure. However, up to 20% to 30% of patients require high dose vasopressor or inotropic support following surgery, enhancing the risk of organ dysfunction and impacting mortality. Nonalcoholic fatty liver disease (NAFLD) is a frequent finding in these patients and may be involved in the pathophysiology of vasoplegia and cardiac failure.

Methods: Retrospective analysis of 463 patients undergoing elective cardiac surgery in 2014 at our institution. NAFLD was defined using the NAFLD fibrosis score and the vasoactive-inotropy score was used to determine postoperative vasopressor and inotropic dependency.

Results: Patients with NAFLD more often presented with high vasopressor or inotropic support compared to patients without NAFLD, resulting in significant differences after 6 hours (n = 20 [27.0%] of 74 patients), 12 hours (n = 20 [27.0%] of 74 patients), and on the first postoperative day (n = 12 [16.4%] of 73 patients) of intensive care unit (ICU) treatment. Multivariate analysis revealed time of catecholamine application (P = .001), preoperative left ventricular ejection fraction (P = .001), type of surgery (P = .001), model of endstage liver disease on hospital admission (P = .002), pre-existing pulmonary hypertension (P = .004) and NAFLD-time interaction (P = .05) as independent predictors of high vasopressor and inotropic support. Patients with NAFLD had higher degrees of extrahepatic organ dysfunction, were more dependent on hemodialysis, spent more days in the ICU and within the hospital. Patients with NAFLD and high catecholamine support had the highest mortality rates among the study population.

Conclusions: NAFLD is a common finding in elective cardiac surgery patients. Anesthesiologists and intensivists should be sensitive for the specific risk profile of this population.

Keywords: cardiopulmonary bypass management; hepatic dysfunction; norepinephrine; postoperative cardiac event.

MeSH terms

  • Aged
  • Cardiac Surgical Procedures* / mortality
  • Cardiopulmonary Bypass*
  • Cardiotonic Agents / administration & dosage
  • Cardiotonic Agents / adverse effects
  • Catecholamines / administration & dosage*
  • Catecholamines / adverse effects*
  • Female
  • Heart Failure / etiology
  • Humans
  • Liver Diseases / etiology*
  • Male
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / complications
  • Postoperative Complications / etiology*
  • Postoperative Period
  • Retrospective Studies
  • Risk
  • Stroke Volume
  • Vasoconstrictor Agents / administration & dosage*
  • Vasoconstrictor Agents / adverse effects*
  • Vasoplegia / etiology
  • Ventricular Function, Left

Substances

  • Cardiotonic Agents
  • Catecholamines
  • Vasoconstrictor Agents